Knowing the unknowns in high risk multiple myeloma

High risk multiple myeloma (HRMM) continues to portend worse outcomes despite the many advances in antimyeloma therapeutics. The optimal approach to treatment is not clearly defined on account of the variable definitions of HRMM and the paucity of studies dedicated to the treatment of HRMM. In this review, we use a case-based approach to review the definitions of HRMM, and evaluate the evidence for induction, stem cell transplantation, and post-transplant therapy approaches for HRMM.

Automated summary

The optimal approach to the treatment of high risk multiple myeloma remains unclear due to variable definitions and limited studies dedicated to its treatment.